Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 232 (7%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3280 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (12%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| ALYSENA 21 | 20MCG 100MCG | TABLET | Resolved | 2024-09-12 | 2024-09-20 | 237351 |
| ALYSENA 21 | 20MCG 100MCG | TABLET | Resolved | 2024-10-24 | 2025-01-10 | 241066 |
| ALYSENA 21 | 100MCG 20MCG | TABLET | Resolved | 2025-07-03 | 2025-08-08 | 261623 |
| ALYSENA 21 | 100MCG 20MCG | TABLET | Resolved | 2025-08-28 | 2025-09-05 | 266072 |
| ALYSENA 28 | 20MCG 100MCG | TABLET | Resolved | 2018-02-26 | 2018-04-12 | 41130 |
| ALYSENA 28 | 20MCG 100MCG | TABLET | Resolved | 2019-05-15 | 2019-09-16 | 84101 |
| ALYSENA 28 | 20MCG 100MCG | TABLET | Resolved | 2020-03-18 | 2020-04-13 | 108920 |
| ALYSENA 28 | 20MCG 100MCG | TABLET | Resolved | 2021-10-08 | 2021-12-13 | 146898 |
| ALYSENA 28 | 20MCG 100MCG | TABLET | Resolved | 2024-11-15 | 2025-01-10 | 243184 |
| ANAFRANIL | 50MG | TABLET | Resolved | 2020-07-07 | 2020-09-03 | 119627 |
| ANAFRANIL | 25MG | TABLET | Resolved | 2020-07-23 | 2020-09-03 | 121017 |
| ANAFRANIL | 25MG | TABLET | Resolved | 2021-02-26 | 2021-03-15 | 134799 |
| ANAFRANIL | 50MG | TABLET | Resolved | 2021-11-22 | 2021-12-20 | 149702 |
| ANAFRANIL | 25MG | TABLET | Resolved | 2022-03-18 | 2022-04-04 | 156980 |
| ANAFRANIL | 50MG | TABLET | Resolved | 2023-10-20 | 2023-12-22 | 207713 |
| ANAFRANIL | 25MG | TABLET | Resolved | 2024-03-15 | 2024-03-22 | 222473 |
| ANTI-NAUSEANT | 50MG | TABLET | Resolved | 2018-02-05 | 2018-09-12 | 38526 |
| APO-ACETAMINOPHEN | 325MG | TABLET | Resolved | 2017-12-05 | 2018-07-03 | 31812 |
| APO-ACETAMINOPHEN | 325MG | TABLET | Resolved | 2019-09-12 | 2019-10-18 | 93665 |
| APO-ACETAMINOPHEN EXTRA STRENGTH | 500MG | TABLET | Resolved | 2017-03-12 | 2017-10-10 | 701 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |